報價延遲最少15分鐘:2025/06/28 15:00 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
131.45 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
1.42/2.75
|
|
企業價值
4.92B
|
| 資產負債 |
|
每股賬面淨值
7.87
|
| 現金流量 |
|
現金流量率
0.01
|
| 損益表 |
|
收益
23.60M
|
|
每股收益
5.67
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/06/28 15:00 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation. |